Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Molecular Mechanisms of Radioresistance in Non-Small-Cell Lung Cancer: Integrating MicroRNA Regulation and Extracellular Vesicle-Mediated Communication

  1. 1Department of Bioscience and Laboratory Medicine, Graduate School of Health Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki 036-8564, Aomori, Japan
  2. 2Research Center for Biomedical Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki 036-8564, Aomori, Japan

Abstract

Radioresistance limits the efficacy of radiotherapy in non-small-cell lung cancer (NSCLC). Its development reflects interactions among DNA damage repair, cell cycle regulation, cell death avoidance, metabolic adaptation, cellular plasticity, and the tumor microenvironment. MicroRNAs (miRNAs) regulate these processes through multiple targets, whereas extracellular vesicles (EVs) may connect intracellular responses with intercellular communication. This review critically examines the molecular mechanisms and experimental models of NSCLC radioresistance, emphasizing miRNA regulation and EV-mediated interactions among cancer, stromal, and immune cells. We distinguish intrinsic resistance from resistance arising through selection and adaptation during repeated irradiation and assess evidence linking miRNA alterations to functional radiation responses. We also evaluate EV-associated extracellular RNA pathways and pathways reported as non-exosomal, separating cargo detection and cellular uptake from functional delivery and sustained resistance. Potential applications include radiosensitization through molecular targeting, circulating biomarkers, and therapeutic delivery. However, clinical translation requires standardized irradiation models, rigorous EV characterization, quantitative assessment of miRNA transfer, and independent clinical validation. Integrating intracellular mechanisms with intercellular signaling may clarify how radioresistance develops and persists, providing a framework for biomarker development and strategies tailored to tumor molecular characteristics. Clinical interpretation also depends on fractionation, molecular background and combined systemic treatments.

Related

  1. Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities
    Tuya Wang, Jing Fu, Ye Huang +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  2. Interplay Between Epigenetics and Reactive Oxygen Species in Tumor Radioresistance: Mechanisms and Therapeutic Strategies for Radiotherapy.
    Zhengmao Yang, Jiaxin Wang, Guofang Wang +3
    Cancer medicinePeer-reviewedCC BY-NCFull textMolecular biology & gene regulationEurope PMCDOAJ
  3. The Tendon Extracellular Matrix: From Hierarchical Architecture to Systemic Regulation and Therapeutic Translation
    BiomoleculesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  4. Extracellular Vesicle-Mediated Local and Systemic Communication in Metabolic Diseases
    Rong-Ping Fan, Li-Ping Gou, Jin-Fang Ma +5
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Molecular biology & gene regulationCrossref
  5. Extracellular vesicles: A complex array of particles involved in cell-to-cell communication for tissue homeostasis
    Natayme Rocha Tartaglia, Lorena Martin-Jaular, Alain Joliot +1
    Cells & DevelopmentPeer-reviewedCC BY-NC-ND 4.0Full text6 citedMolecular biology & gene regulationHAL
BibTeX
@article{ishikawa2026molecular,
  title = {{Molecular Mechanisms of Radioresistance in Non-Small-Cell Lung Cancer: Integrating MicroRNA Regulation and Extracellular Vesicle-Mediated Communication}},
  author = {Mei Ishikawa and Mitsuru Chiba},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210240},
  url = {https://www.mdpi.com/1422-0067/27/22/10240},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Molecular Mechanisms of Radioresistance in Non-Small-Cell Lung Cancer: Integrating MicroRNA Regulation and Extracellular Vesicle-Mediated Communication
AU  - Mei Ishikawa
AU  - Mitsuru Chiba
PY  - 2026
DA  - 2026/11/15
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210240
UR  - https://www.mdpi.com/1422-0067/27/22/10240
AB  - Radioresistance limits the efficacy of radiotherapy in non-small-cell lung cancer (NSCLC). Its development reflects interactions among DNA damage repair, cell cycle regulation, cell death avoidance, metabolic adaptation, cellular plasticity, and the tumor microenvironment. MicroRNAs (miRNAs) regulate these processes through multiple targets, whereas extracellular vesicles (EVs) may connect intracellular responses with intercellular communication. This review critically examines the molecular mechanisms and experimental models of NSCLC radioresistance, emphasizing miRNA regulation and EV-mediated interactions among cancer, stromal, and immune cells. We distinguish intrinsic resistance from resistance arising through selection and adaptation during repeated irradiation and assess evidence linking miRNA alterations to functional radiation responses. We also evaluate EV-associated extracellular RNA pathways and pathways reported as non-exosomal, separating cargo detection and cellular uptake from functional delivery and sustained resistance. Potential applications include radiosensitization through molecular targeting, circulating biomarkers, and therapeutic delivery. However, clinical translation requires standardized irradiation models, rigorous EV characterization, quantitative assessment of miRNA transfer, and independent clinical validation. Integrating intracellular mechanisms with intercellular signaling may clarify how radioresistance develops and persists, providing a framework for biomarker development and strategies tailored to tumor molecular characteristics. Clinical interpretation also depends on fractionation, molecular background and combined systemic treatments.
SN  - 1422-0067
ER  -